Glioblastoma Multiforme Market (2026–2030): Growth and Competitive Landscape

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Glioblastoma Multiforme Market Expected To Reach Based On Its 2026 Value?

The glioblastoma multiforme market size has seen robust growth over the past few years. It is anticipated to increase from $2.7 billion in 2025 to $2.92 billion in 2026, registering a compound annual growth rate (CAGR) of 8.1%. This historical expansion can be attributed to factors such as limited treatment options, developments in neuro-oncology, the standardization of chemotherapy, an increase in cancer research centers, and improvements in imaging technologies.

The glioblastoma multiforme market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $3.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period is primarily driven by factors such as the emergence of innovative targeted pharmaceuticals, the broadening scope of immunotherapy investigations, the integration of individualized cancer therapies, enhanced financial support for brain cancer studies, and a sharpened emphasis on improving patient survival rates. Key trends expected throughout this period encompass a heightened concentration on targeted cancer treatments, the increasing implementation of multi-modal therapeutic strategies, the advancement of precision oncology studies, the wider integration of sophisticated imaging diagnostics, and improved engagement in clinical trials.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Key Factors Are Driving The Glioblastoma Multiforme Market Growth?

The growing prevalence of brain disorder cases is projected to drive the glioblastoma multiforme market moving forward. A brain disorder is defined as a condition impacting the brain’s structure or function, leading to cognitive, emotional, or physical impairments. The increase in brain disorder instances is attributed to factors such as aging demographics, extended life expectancy, lifestyle choices, and advancements in diagnostic capabilities. A deeper understanding of brain disorders aids in advancing research on glioblastoma multiforme (GBM), resulting in enhanced early detection, innovative treatment options, and improved patient outcomes. By examining neurological conditions, scientists can discover genetic and molecular correlations that contribute to GBM development. For example, in February 2025, as reported by Dementia Australia, an Australia-based non-profit organization, roughly 433,300 Australians are living with dementia, and this figure is expected to surge to 812,500 by 2054. Moreover, younger-onset dementia affects approximately 29,000 people in 2025, with forecasts suggesting an escalation to 41,000 by 2054. Hence, the increasing number of brain disorder cases will fuel the growth of the glioblastoma multiforme market.

Which Segments Define The Glioblastoma Multiforme Market Segment Structure?

The glioblastoma multiforme market covered in this report is segmented –

1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes

2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools

3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types

4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users

Subsegments:

1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites

2) By Temozolomide: Branded (Temodar), Generic Temozolomide

3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)

4) By Lomustine: Branded (Gleostine), Generic Lomustine

5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy

Which Trends Are Guiding The Direction Of The Glioblastoma Multiforme Market?

Key companies operating in the glioblastoma multiforme market are concentrating on developing advanced treatments, such as CAR T-cell therapies, to address critical unmet medical needs in aggressive cancer. CAR T-cell therapies are a type of immunotherapy that involves modifying a patient’s T-cells to more effectively target and eliminate cancer cells. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, initiated a Phase IB clinical trial for its CHM 1101 (CLXT CAR T) therapy, intended for recurrent or progressive glioblastoma multiforme (GBM). This multi-center trial aims to assess the therapy’s safety and efficacy, while also determining the recommended Phase 2 dose. Initial Phase 1a results demonstrated disease stability, and the current trial will expand upon these findings to support continued development. The company intends to leverage this data to design a registration trial and obtain regulatory feedback.

Who Are The Established Players Within The Glioblastoma Multiforme Market?

Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.

Get The Full Glioblastoma Multiforme Market Report:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Which Region Is The Top Contributor To The Glioblastoma Multiforme Market By Share?

North America was the largest region in the glioblastoma multiforme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Glioblastoma Multiforme Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report

Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2026, By The Business Research Company

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Glioblastoma Multiforme Gbm Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Glioma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795